Across TCGA pan-cancer cohorts, AKR1C3 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated AKR1C3 data layer compared with 25 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher AKR1C3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated AKR1C3 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LIHC show a favorable association.

STAD, UCEC, and BLCA are the cancer types where AKR1C3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	II,III,IV	0.001	0.660	<.001	36	view →
UCEC	DFS	Median	II,III,IV	1.000	0.443	.033	8	view →
BLCA	DFS	Median	III,IV	0.132	0.572	.015	6	view →
PRAD	DFS	Median	All	0.224	0.775	.033	4	view →
LIHC	DFS	Median	All	1.000	0.256	.037	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: AKR1C3 tumor-vs-normal RNA expression · all AKR1C3 data types